The FDA has expanded the use of bevacizumab (Avastin) for treatment resistant metastatic colorectal cancer.  Results from a clinical trial  demonstrated that the drug improved overall survival by 19% compared to patients who received chemotherapy alone.  It also improved progression-free survival by 32%.  What other conditions is Avastin indicated for?

For more information, please visit San Francisco Business Times.